Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) have earned an average recommendation of "Hold" from the seventeen analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $8.93.

SAGE has been the subject of a number of research reports. Wall Street Zen lowered Sage Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 7th. Robert W. Baird raised their target price on Sage Therapeutics from $7.00 to $9.00 and gave the company a "neutral" rating in a research note on Friday, June 20th. Canaccord Genuity Group lifted their price objective on Sage Therapeutics from $8.00 to $8.50 and gave the stock a "hold" rating in a research report on Tuesday, June 17th. Truist Financial set a $9.00 price objective on Sage Therapeutics and gave the stock a "hold" rating in a research report on Tuesday, June 17th. Finally, Piper Sandler lowered Sage Therapeutics from a "strong-buy" rating to a "hold" rating and lowered their price objective for the stock from $9.00 to $8.50 in a research report on Tuesday, June 17th.

Hedge Funds Weigh In On Sage Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its holdings in Sage Therapeutics by 16,118.0% during the first quarter. GAMMA Investing LLC now owns 8,109 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 8,059 shares during the last quarter. Millennium Management LLC boosted its holdings in Sage Therapeutics by 8.3% during the fourth quarter. Millennium Management LLC now owns 1,623,785 shares of the biopharmaceutical company's stock worth $8,817,000 after buying an additional 124,720 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Sage Therapeutics by 31.2% during the fourth quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company's stock worth $99,000 after buying an additional 4,350 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in Sage Therapeutics by 108.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company's stock worth $405,000 after buying an additional 38,876 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Sage Therapeutics by 9.3% during the 4th quarter. BNP Paribas Financial Markets now owns 77,560 shares of the biopharmaceutical company's stock valued at $421,000 after purchasing an additional 6,574 shares in the last quarter. Institutional investors own 99.22% of the company's stock.

Sage Therapeutics Price Performance

Shares of NASDAQ:SAGE traded up $0.12 during midday trading on Friday, reaching $9.20. The company's stock had a trading volume of 3,011,754 shares, compared to its average volume of 1,306,909. Sage Therapeutics has a fifty-two week low of $4.62 and a fifty-two week high of $13.47. The company has a market capitalization of $575.80 million, a P/E ratio of -1.59 and a beta of 0.29. The business's fifty day simple moving average is $7.53 and its 200-day simple moving average is $7.24.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 747.63% and a negative return on equity of 68.99%. The business had revenue of $14.06 million during the quarter, compared to analyst estimates of $14.12 million. During the same quarter last year, the business posted ($1.80) earnings per share. The business's quarterly revenue was up 78.0% compared to the same quarter last year. On average, analysts forecast that Sage Therapeutics will post -3.52 earnings per share for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.